Navigation Links
Roswell Park Spinoff Company Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM
Date:11/22/2019

The inventors of a new and unique cancer immunotherapy developed at Roswell Park Comprehensive Cancer Center have announced a major step forward with that therapy, known as SurVaxM. MimiVax LLC principals Robert Fenstermaker, MD, and Michael Ciesielski, PhD, have announced that the company, spun off from Roswell Park in 2012, has entered into a China-exclusive licensing agreement for SurVaxM with Shanghai Fosun Pharmaceutical (Group) Co. Ltd., based in Shanghai, China.

Under the terms of the agreement, Fosun Pharma and MimiVax will work to develop and commercialize SurVaxM for patients in the U.S. and specified territories in China. A $10 million upfront payment made to MimiVax will enable and partially fund the upcoming pivotal clinical trials in both the U.S. and China. MimiVax is eligible to receive an additional $28 million in developmental milestones and $110 million in sales milestones.

SurVaxM, which MimiVax is developing based on technology licensed from Roswell Park, is an immunotherapy designed to stimulate the immune system to kill tumor cells that contain survivin, a protein that helps cancer cells to resist conventional treatments. The drug, which is manufactured in the United States, has been studied most extensively in patients with glioblastoma, an aggressive and hard-to-treat brain cancer, but the drug’s target, survivin, is also present in many other types of cancer, including multiple myeloma, neuroendocrine, medulloblastoma, melanoma, kidney and breast tumors.

Based upon positive results from initial phase I and phase II studies, the team expects to advance to large, multicenter randomized phase II trials in the coming year both in China and in the U.S. A single-arm phase II study in 63 patients with newly diagnosed glioblastoma last year demonstrated significantly longer survival time for patients treated with SurVaxM, with 93.5% alive a year after diagnosis, compared to expected 65% survival based on historical studies.

“Immunotherapies are changing the way we treat many cancers, but none of the FDA-approved immunotherapies are an option for patients with glioblastoma, and the approved treatment options we do have for patients with the disease remain quite limited both in number and in effectiveness,” says Dr. Fenstermaker, who is Chair of Neurosurgery at Roswell Park and Chief Medical Officer of MimiVax.

“We’re grateful to Fosun Pharma for recognizing the promise that SurVaxM holds, and eagerly look forward to working with our partners both in the United States and China to get these additional clinical studies underway,” adds Dr. Ciesielski, who is Assistant Professor of Neurosurgery at Roswell Park and Chief Executive Officer of MimiVax.

Drs. Ciesielski and Fenstermaker gratefully acknowledge donations to Roswell Park in support of their research at critical early stages.

“We’re so grateful for the community’s generous and enthusiastic support of this work,” adds Dr. Fenstermaker. “The initial laboratory investigations that paved the way to where we are now would not have been possible without individual donors who contributed to fundraising efforts like The Ride For Roswell.”

This release is also available on the Roswell Park website: https://www.roswellpark.org/newsroom/201911-roswell-park-spinoff-company-advances-toward-new-clinical-trial-brain-cancer

About MimiVax LLC
MimiVax LLC is a NY based private, clinical-stage biotechnology company formed in 2012 to develop and commercialize its lead candidate SurVaxM and pipeline immunotherapeutics for cancer and autoimmune diseases. For more information visit http://www.mimivax.com.

About Roswell Park
Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at http://www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.

Read the full story at https://www.prweb.com/releases/roswell_park_spinoff_company_advances_toward_new_clinical_trial_for_brain_cancer_immunotherapy_survaxm/prweb16737735.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Research spinoff ReXceptor gets license for Alzheimers treatment
2. Fenbushi Capital and DF Capital Back Blockchain and Cryptoasset Data Company Amberdata
3. VetStem Biopharma Enters Pet Cancer Field with Key License from Leading Human Cancer Company, Calidi Biotherapeutics
4. Leading Boston-Based Conference Company and Publisher Expands Portfolio Internet of Things (IoT)
5. PureWay Hires New Vice President of Sales to Spearhead Company Growth
6. Lifecycle Biotechnologies Releases Company Catalog
7. Nanomedical Diagnostics Announces Office Move to Accommodate Company Growth
8. Superior Controls - First Company Globally to Achieve CSIA Certification for the Seventh Consecutive Time
9. Murrieta Genomics Welcomes Second Genomic Sequencing Incubator Company
10. Plum Alley Closes $1.5M in Syndicate with Women and Men Investing in CRISPR-based Diagnostics Company
11. MedNet Solutions Named Most Outstanding eClinical Solutions Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/12/2019)... ... November 12, 2019 , ... In’Tech Medical SAS ( http://www.intech-medical.com ... creation of a Global Regulatory Affairs Department, to support Medical Device companies across ... regulatory element to any Medtech organization is more important than Research & Development, ...
(Date:11/12/2019)... ... November 12, 2019 , ... Atlantic ... purifiers, announced today that distributors voted their patented automatic and manual wipers the ... purifiers. , The most frequent maintenance task required of an ultraviolet water purifier ...
(Date:11/7/2019)... ... November 07, 2019 , ... R3 Stem Cell is now ... the rest of 2019. The code to use during checkout is FIFTYOFF and applies ... is the nation’s leader in regenerative therapies with over 12,000 successful stem cell procedures ...
Breaking Biology News(10 mins):
(Date:12/4/2019)... ... ... Bold Brahim aka Jesse, a Spanish Arabian, was 11 years old when ... medical management, his condition worsened so his owner, Diane, sought a bone scan and ... had a severe injury to his deep digital flexor tendon in his right front ...
(Date:11/27/2019)... , ... November 25, 2019 , ... ... has announced the company’s first robotic-assisted and navigated surgery in the UK. The ... (NHS) by acclaimed spine surgeons, Dr. Syed Aftab and Dr. Alexander Montgomery. The ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... that they have been selected by Lantern Pharma to provided preclinical screening and ... obtain millions of data points using panels of unique and genetically edited cell ...
(Date:11/9/2019)... BOSTON (PRWEB) , ... November ... ... provider of artificial intelligence (AI)-powered technology for use in pathology research, today ... in liver biopsy samples from patients enrolled in the phase 3 selonsertib ...
Breaking Biology Technology: